Aug 12 (Reuters) - Bio-Techne beat Wall Street estimates for fourth-quarter revenue on Wednesday helped by growth in its research and diagnostics businesses. Here are some details: • Bio-Techne is in ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results , with sales up 1.3% year on year to $321.2 million ...

Bio-Techne's (TECH) fiscal Q4 organic revenue growth of 3% is consistent with the progressive improvement story reflected in management's expectation of fiscal 2027 being a roughly 6% sales growth ...

Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

For more information on Bio-Techne and its brands, please visit or follow the company on social media at LinkedIn , X , or YouTube . Forward Looking Statements: Our press releases may contain forward ...

An integrated assay using proprietary RNAscope™ and miRNAscope™ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs. Small regulatory RNAs, ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.